Dr.NALLASIVAM PALANISAMY, MSC. MPHIL. PHD.
My memories about SSV Boys High School
I attended SSVBHS for my 6thstd to 11th std (SSLC) from 1970-1975
I would like to thank all my teachers who has provided me the basic education which laid a strong foundation to further my academic studies and build a successful research career as a scientist in cancer research.
Special thanks to all my teachers
6th Grade-Mr.Gurusamy-1970
7th Grade-Mr.Kuppusamy-1971
8th Grade- Rama Rathina Velusamy-1972
9th Grade-Mr.Murugan-1973
10th Grade-Mr.Paramasivam-1974
11th Grade-1975-76
KM Periasamy-Headmaster
P.Kandasamy-Mathematics
K.Sivasubramanian-Geography
P. Jegadeesan-Biology
K.Ganapathy-Mathematics
L.Subramanian-History
A.Palanisamy-Physics
Arunachalam-Tamil
Loganathan-Physical Training
Marimuthu-Physical Training
Palanisamy-Physical Training
SSVBHS – SSLC 1975-76 Batch – I am sitting the first row (red dot)
NALLASIVAM PALANISAMY, MSC. MPHIL. PHD.
Associate Scientist Associate Professor (Adjunct)
Department of Urology Department of Pathology
Henry Ford Health System Michigan Center for Translational Pathology
Vattikuti Urology Institute University of Michigan
Mailing Address
Department of Urology
Henry Ford Health System
One Ford Place, Room 2D26
Phone: 313 874 6396 (Office)
Cell: 313 817 8294 (O); 734 358 9507(P)
Email: npalani1@hfhs.org; nallasiv@med.umich.edu
EDUCATION AND TRAINING
06/1979-06/1981 University of Madras, Chennai, India
B.Sc., Zoology
06/1981- 06/1983 University of Madras, Chennai, India
M.Sc., Zoology
06/1983- 06/1984 University of Madras, Chennai, India
M.Phil.Human Genetics
05/1985-10/1993 University of Madras, Chennai, India
Ph.D., Human Genetics
09/1990-05/1991 Postdoctoral Research Associate
Molecular Biology
University of Vermont, Burlington, VT, USA
12/1993-04/1996 Postdoctoral Research Associate
Molecular Biology
Miami Children’s Hospital Research Institute, Miami, FL, USA
05/1996 –11/1999 Postdoctoral Research Associate
Cancer Cytogenetics/Molecular Cytogenetics
Memorial Sloan-Kettering Cancer Center, New York City, NY, USA
07/2000-06/2002 American Board of Medical Genetics training program in Clinical Cytogenetics: Memorial Sloan–Kettering Cancer center, New York, N.Y.
07/2001 42nd Annual course in Medical and experimental mammalian genetics, Jackson Laboratory co-organized with Johns Hopkins University, Bar Harbor, Maine, USA.- Course Director Victor A. McKusick.
01/2009-03/2009 MBAEE – MBA Essentials and Entrepreneurship
Michigan Ross School of Business
University of Michigan, Ann Arbor, MI
CERTIFICATION AND LICENSURE
10/2000 –11/2007 Certificate of Qualification for Laboratory Director in Cytogenetics, New York State Department of Health
ACADEMIC APPOINTMENTS
10/1991 – 11/1993 Cytogeneticist, Institute of Laboratory Sciences
Kovai Medical Center and Hospital Ltd, Coimbatore, India
12/1999 – 03/2000 Senior Scientist, Research & Development
Cancer Genetics Inc. Cambridge, MA, USA
04/2000 – 07/2004 Director, Research & Development
Director, Genomics Research & Services
Cancer Genetics Inc., Milford, MA, USA
08/2004 – 08/2007 Group Leader, Cancer Biology,
Genome Institute of Singapore, Singapore
08/2005 –08/2007 Adjunct Assistant Professor
School of Biological Sciences
Nanyang Technological University, Singapore
08/2007-08/2008 Consultant Molecular Cytogeneticist
Genome Institute of Singapore, Singapore
08/2007-08/2012 Assistant Professor of Pathology
Michigan Center for Translational Pathology
Department of Pathology
University of Michigan Medical School
09/2012-9/2014 Associate Professor of Pathology
Michigan Center for Translational Pathology
Department of Pathology
University of Michigan Medical School
University of Michigan, Ann Arbor, MI
10/2014 -Present Associate Scientist
Vattikuti Urology Institute
Department of Urology
Henry Ford Health System
Detroit, MI
03/2014-03/2015 Visiting Professor
Department of Food and Nutrition Sciences
King Saud University
Riyadh, Saudi Arabia
01/2015- Present Associate Professor (Adjunct)
Michigan Center for Translational Pathology
Department of Pathology
University of Michigan Medical School
University of Michigan, Ann Arbor, MI
Research Grants
Active
PI: PALANISAMY, NALLASIVAM
1R21CA176330-01; 4/1/2014-3/31/2016
FUNCTIONAL CHARACTERIZATION OF PSEUDOGENES AS NEW BIOMARKER IN PROSTATE CANCER
Previously funded grants (28)
- PI: PALANISAMY, NALLASIVAM
5R44CA08483804
FISH ASSAY FOR THE DETECTION OF T (14;18) (Q32;21)
CANCER GENETICS, INC. 2003 NCI
$195,529
- PI: PALANISAMY, NALLASIVAM
5R44CA08483803
FISH ASSAY FOR THE DETECTION OF T (14;18) (Q32;21)
CANCER GENETICS, INC. 2002 NCI
$381,724
- PI: PALANISAMY, NALLASIVAM
2R44CA08483802
FISH ASSAY FOR THE DETECTION OF T (14;18) (Q32;21)
CANCER GENETICS, INC. 2001 NCI
$417,956
- PI: PALANISAMY, NALLASIVAM1R43CA08997001
MOLECULAR PROBES FOR BURKITT’S AND MANTLE CELL LYMPHOMA
CANCER GENETICS, INC. 2001 NCI
$158,425
- PI: PALANISAMY, NALLASIVAM
1R43CA09153201
FISH ASSAY FOR ACUTE MYELOID LEUKEMIA
CANCER GENETICS, INC. 2001 NCI
$226,508
- PI: PALANISAMY, NALLASIVAM
1R43CA09436301
HIGH THROUGHPUT SYSTEM FOR FISH ANALYSIS
CANCER GENETICS, INC. 2002 NCI
$186,145
- Project Director: PALANISAMY, NALLASIVAM
RFP-1108-17- 2, 3 07/01/01-05/27/02
NIH/NCI
Spectral Karyotyping (SKY), Comparative Genomic Hybridization (CGH), and Fluorescent in situ hybridization (FISH) analysis. National Cancer Institute Subcontract between Bio-Reliance Corporation and Cancer Genetics, Inc. for two projects: Project 1. “Cytogenetic Biomarkers in Peripheral Blood Lymphocytes and Risk of Non-Hodgkin’s Lymphoma; Project 2. “A Cross-sectional Study of Occupational Exposure to Benzene and Un-banded Chromosomal Aberrations in Peripheral Blood Lymphocytes Among workers in China”
- PI: PALANISAMY, NALLASIVAM
Ventana-Roche Sponsored Research Project
Role: Principal Investigator 06/12-05/13
ETV1 ISH and Antibody Assay Development $42,210
Goal(s): RNA ISH and FISH Assay development for ETV1in prostate cancer
- PI: PALANISAMY, NALLASIVAM
Ventana-Roche Sponsored Research Project
Role: Principal Investigator 11/2013-10/2014
ETV1 ISH and Antibody Assay Development $54,000
Goal(s): RNA ISH and FISH Assay development for ETV1in prostate cancer
- PI: PALANISAMY, NALLASIVAM 08/01/11-07/31/13
Gen-Probe, Inc. $514,470/yr
University of Michigan/Gen-Probe Partnership to Develop Gene Fusion Based Diagnostics for Prostate Cancer.
Goal(s): Assist Gen-Probe in the development of a urine-based gene fusion test for prostate cancer.
- PI: PALANISAMY, NALLASIVAM 3/29/10-8/4/2011
GlaxoSmithKline (GSK) $191,205.00
Goals: Validation of ETS gene fusions
Molecular Profiling of ETS Gene Rearrangement in Prostate Cancer Patients Registered in the REDEEM and REDUCE Clinical Trial
- PI: PALANISAMY, NALLASIVAM 01/01/10-03/31/10
Ventana $127,484/yr.
Validation Studies in Support of the development of Multi-Probe Fish Assays in Prostate Cancer-ETS Partners
Goal(s): Development of FISH assay for detection of prostate cancer translocations
- PI: PALANISAMY, NALLASIVAM 06/01/09-05/31/10
Melanoma Research Alliance $50,000/yr.
Development Award
Transcriptome Sequencing to Detect Gene Fusions in Melanoma
Goal(s): An integrated analysis combining genomic copy number changes and transcriptome analysis to discover novel nuclear markers for malignant melanoma
- PI: PALANISAMY, NALLASIVAM 05/01/09-04/30/10
Agilent Technologies $48,537/yr.
Combined use of aCGH and genome partitioning to identify and characterize recurrent genomic amplifications in prostate cancer: identification and sequence characterization of oncogenic and tumor suppressive events.
- PI: PALANISAMY, NALLASIVAM 05/06-04/07
Agilent Technologies $30,000
Molecular Characterization of Breast Cancer Genome
- PALANISAMY, NALLASIVAM- PI Career Development Award- University of Michigan Prostate SPORE
P50CA-069568 (PI: Pienta) 11/01/10-10/31/12
NIH/NCI $83,147/yr.
Career Development Award Prostate Spore: Molecular Characterization of ETS Negative Prostate Cancer
Goal(s): 1) To identify recurrent gene fusions in ETS negative prostate cancer by transcriptome sequencing approach using Illumina Hiseq; 2) To follow up previously identified gene fusions in recurrence screening and functional characterization to establish their role in prostate cancer; 3) To interrogate transcriptome landscape for differential expression of novel non-coding RNA, splice variants, novel transcripts and SNP analysis.
- W81XWH-11-1-0520 (PI: Wicha) 05/01/11-04/30/12
Department of Defense $443,618/yr.
National Functional Genomics Center – A center for Genetic origins of cancer (CGOC) at the University of Michigan
Goal(s): to develop a comprehensive approach to genetics, proteomics and bioinformatics that can help elucidate the mechanisms driving tumorigenesis. This research investigates the notion that cancer stem cells are the key cell component driving tumorigenesis, metastasis and treatment resistance.
Role: Co-Investigator
- W81XWH-08-1-0031 (PI: Chinnaiyan) 04/15/08 – 07/14/11
Department of Defense $121,746/yr.
Characterization of SPINK1 in Prostate Cancer
Role: Co-Investigator
- W81XWH-09-2-0014 (PI: Wicha) 03/01/09 – 04/05/11
Department of Defense $350,000/yr.
National Functional Genomics Center
Goal(s): to develop a comprehensive approach to genetics, proteomics and bioinformatics that can help elucidate the mechanisms driving tumorigenesis. This research investigates the notion that cancer stem cells are the key cell component driving tumorigenesis, metastasis and treatment resistance.
Role: Co-Investigator
- R33 CA126966-01 (PI: Liu) 02/07-02/10
NIH-NCI $1,312,362
Paired End DI Tag Technologies for the Complete Annotation of Fusion Genes
Role: Co-Investigator
- PI: Huynh Hung 04/07-04/09
Singapore Cancer Syndicate Programme Initiative 2007 $1,708,000
Hardening the national xenograft therapeutic program: expansion of HCC xenograft infrastructure, drug evaluation, cell line generation and linkage to primary HCC’s via genomic analysis.
Role: Co- Investigator
- 1UM1HG006508-01A1 (PI: Chinnaiyan) NIH 7/19/2013 to 5/13/2017
Exploring precision cancer medicine for sarcoma and rare cancers
Role: Co-investigator
- R01-CA-107469-06-A1 (PI: Kleer) NIH/NCI 07/01/10 – 04/30/15
The Role of EZH2 in Breast Cancer Progression $278,389/yr.
Goal(s): Elucidate the function of EZH2 in breast cancer progression and metastasis and its prognostic utility.
Role: Co-investigator
- U01CA111275-06 (PI: Chinnaiyan) NIH/NCI 08/01/10 – 06/30/15
Goal(s): extending our work in the discovery and refinement of biomarkers to facilitate the accurate diagnosis of prostate cancer using the TMPRSS2-ETS rearrangements as a foundation. Develop biomarkers to predict aggressive prostate cancer with the goal of distinguishing indolent from aggressive prostate cancer either prior to diagnosis or at the time of biopsy diagnosis.
Role: Co-Investigator
- RO1 CA154365-01 (PIs: Beer and Chinnaiyan) NIH 04/01/11-03/31/16
Identification and characterization of gene fusions in lung adenocarcinoma $185,000/yr.
Goal(s): To identify new gene fusions in lung cancer utilizing a newly developed bioinformatics approach combined with next-generation sequencing data.
Role: Co-Investigator
- PI: Maha Hussain
PROSTATE Cancer Foundation 9/1/2013 – 9/1/2015
Role: Co-Investigator
Co-targeting the cell cycle and androgen signaling axis via CDK4/6 inhibition: A novel paradigm for treating metastatic hormone-sensitive prostate cancer
- PI: Scott Tomlins
Department of-Army, Department of the Defense 7/1/14-6/30/17
Clonal evaluation of prostate cancer by ERG/SPINK1 status to improve prognosis prediction (PC130652)
Role: Co-Investigator
- PI: Arul Chinnaiyan 2/12/2014 – 1/31/2017
1UO1CA-183027-01 -NIH
Integrative molecular imaging and sequencing of prostate cancer
Role: Co-Investigator
HONORS AND AWARDS
1983 First Prize for Merit in M.Sc., Zoology (1983)
Kongunadu Arts and Science College, University of Madras
1985-1987 Junior Research Fellowships (JRF) Award
1987-1990 Senior Research Fellowship (SRF) Award, Council of Scientific and Industrial Research (CSIR), New Delhi, India.
2000-2003 Small Business Innovative Research (SBIR) Grant awards, funded by National Cancer Institute, National Institutes of Health-NIH (Phase I: 3; Phase II: 1)
2006 Agilent Technologies University Relations Grant Award
2008 Best Reviewer Award- Singapore Medical Journal
2009 Melanoma Research Alliance Development Award
2009 Agilent Technologies University Relations Grant Award
2010-2012 Career Development Award
University of Michigan Comprehensive Cancer Center Prostate Cancer SPORE
2011 Who’s Who in America-Marquis – 2011, 65th Edition (pub.2010)
2011 Recognition of Professional Development Award, University of Michigan, Department of Pathology “REWARD” – Employee Recognition Program
2013 Recognition of Professional Development Award, University of Michigan, Department of Pathology “REWARD” – Employee Recognition Program
2015- Member, Josephine Ford Cancer Institute (JFCI), Henry Ford Health System, Detroit, MI
2015- Member, Karmanos Cancer Institute, Wayne State University, Detroit, MI
MEMBERSHIP IN PROFESSIONAL SOCIETIES
1997-2004 Associate Member in American Society of Human Genetics (ASHG)
1997 Associate Member in American Association for Cancer Research (AACR)
2009-present Active Member in American Association for Cancer Research (AACR)
2015-present Active Member in Society for Basic Urological Research
2015-present Active Member in American Association for the Advancement of Science (AAAS)
EDITORIAL POSITIONS, BOARDS, PEER-REVIEW SERVICE
Journal of Rashid Latif Medical College, Lahore, Pakistan International Advisory Board
Online Journal of Bio Sciences and Informatics Editorial Board
American Journal of Cancer Genetics, Genomics and Proteomics Senior Editorial Board
American Journal of Cancer Science Senior Editorial Board
American Journal of Cancer Biology Senior Editorial Board
International Journal of Chronic Diseases Editorial Board
Frontiers in Toxicogenomics Editorial Board
Journal of Case Reports and Studies Editorial Board
International Journal of Forensic Science & Pathology (IJFP) Editorial Board
Human Pathology-Case Reports Editorial Board
Pathology and Laboratory Medicine Editorial Board
International Clinical Pathology Journal Editorial Board
Singapore Medical Journal Reviewer
Biomed Central-Cancer Reviewer
Cancer Research Reviewer
Clinical Cancer Research Reviewer
Oncogene Reviewer
Oncotarget Reviewer
Genetic Testing Reviewer
Medical Hypotheses Reviewer
Journal of Cancer Research and Therapy Reviewer
Advances in Biology Reviewer
PLoS One Reviewer
Indian Journal of Clinical Biochemistry Reviewer
Gene Reviewer
Proceedings of the National Academy of Sciences Reviewer
Journal of Translational Medicine Reviewer
Proteomics-Clinical Applications Reviewer
Clinical Nephrology and Urology Science Reviewer
Chinese Journal of Cancer Research Reviewer
PHD THESIS DISSERTATION COMMITTEES – served as thesis review examiner for 17 PhD thesis from
University of Madras, Chennai, Tamilnadu, India,
Anna University of Technology, Thiruchirapalli, Tamilnadu, India
Bharathiar University, Coimbatore, Tamilnadu, India
University of Miami, FL, USA
The Tamilnadu Dr. MGR Medical University, Tamilnadu, India
National University of Singapore, Singapore
Presented 63 seminars and extramural invited presentations-
PATENTS
- United States Patent: 7,585,964 –Granted, September 8, 2009
Methods of analyzing chromosomal translocations usingfluorescence in situ hybridization (FISH). Inventors: Nallasivam Palanisamy and Raju S. Chaganti
- United States Patent: 7,964,345 –Granted, June 21, 2011
Methods of analyzing chromosomal translocations usingfluorescence in situ hybridization (FISH). Inventors: Nallasivam Palanisamy and Raju S. Chaganti.
- United States Patent: 8,945,556 – Granted, February 3, 2015
RAF Gene Fusions.
Inventors: Arul M. Chinnaiyan, Nallasivam Palanisamy and Shanker Kalyana-Sundaram.
- United States Patent Application filed on December 19, 2002. Application # 20020192692.
Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (FISH). Inventors: Nallasivam Palanisamy and Raju S. Chaganti, Institution: Cancer Genetics, Inc., USA.
- United States Patent application filed on September 29, 2005. Application #: 20050214842.
Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (FISH)
Inventors: Nallasivam Palanisamy and Raju S. Chaganti. Institution: Cancer Genetics, Inc., USA
- United States Patent application filed on July 19, 2007. Application #:20070166749.
Methods of analyzing chromosomal translocations using fluorescence in situ hybridization (FISH). Inventors: Nallasivam Palanisamy and Raju S. Chaganti. Institution: Cancer Genetics, Inc., USA
- Canadian Patent Publication number: CA2447320 A1 PCT number; PCT/US2002/015492 Publication date: Nov 21, 2002, Filing date May 14, 2002 Priority date May 14, 2001. Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)
Inventors: Nallasivam Palanisamy and Raju S. Chaganti. Institution: Cancer Genetics, Inc., USA.
- International Patent application filed on 10/22/2007Application #: 20100285475. “Fused Genes”. Application #: PCT/ SG2007/00036.
Inventors: Nallasivam Palanisamy, Edison Liu, Kalpana Ramnarayanan
- United States Patent Application filed on November 11, 2010. “Fused Genes.” Application #:20100285475. Inventors: Nallasivam Palanisamy, Kalpana Ramnarayanan and Edison Liu.
- United States Patent Application filed on December 11, 2014: Application #:20140364481.RNA chimeras in human leukemia and lymphoma. Kojo Elenitoba-Johnson, Thirunavukkarasu Velusamy, Nallasivam Palanisamy, Anagh Sahasrabuddhe, Megan Lim, Arul Chinnaiyan
- United States Patent Application publication on July 9, 2015: Publication No: US2015/0191795 A1. RAF Gene Fusions. Arul Chinnaiyan, Nallasivam Palanisamy, Shanker Kalyana-Sundaram
Published 98 peer-reviewed publication in international research journals.
Book Chapters
- Palanisamy N, Marimuthu, KM, Prema L: A case of mosaic trisomy X and fragile site at 5q with congenital heart disease. Contemporary studies in Human Genetics, Ed. by S.B.Roy et.al, p-26-28, 1987
- Palanisamy N, Marimuthu KM, Prema L: Congenital heart disease in Down syndrome. Contemporary studies in Human Genetics, Ed. by S.B.Roy et al., p-29-36, 1987
- Palanisamy N. Ring chromosome 3. A report of a case with features of Cornelia de -Lange syndrome. Genetics – Perspectives in Man and Environment. Ed. By ST Santhiya and G Jeyaraman, University of Madras, p-8-9, 1990
- Palanisamy N. Chromosomal Translocations in AML: Detection and Prognostic Significance. Genetics, Biology and Therapy of Acute Myelogenous Leukemia, Ed.Nagarajan L. In the Cancer Treatment and Research Series Springer-Verlag, 2009; 145:41-58.
- Nanjangud G, Palanisamy N, Chaganti RSK. Cytogenetic analysis and related techniques in hematopathology. Diagnostic Hematopathology. Elaine S.Jaffe, Nancy Harris, James W. Wardiman, Elias Campo and Daniel A. Arber. Elsevier Inc. 2010.
- Chinnaiyan AM, Palanisamy N. “Chromosomal aberrations in solid tumors”. Progress inMolecular Biology and Translational Science (PMBTS), 2010; 95:55-94.Edited by Raymond Ruddon. Editor-in-Chief: Michael Conn Elsevier Inc. 2010.
Books (Thesis)
- Palanisamy N. Cytogenetics studies on selected heart diseases. M.Phil Thesis. University of Madras, Chennai, India. 1984
- Palanisamy N. Genetics of Congenital Heart Diseases. Ph.D. Thesis. University of Madras, Chennai, India. 1993
Other Media
1.“High-Resolution Analysis of Genomic Imbalances in the Cancer Genome”
http://agilent.cnpg.com/lsca/webinar/palanisamy/20080310/
http://www.chem.agilent.com/en-us/events/en-us/pages/13912e.aspx. June, 2007.
- “Divide and Conquer: Molecular Classification of Prostate Cancer”
http://ukcancerconvention.org/ prostate/index.html. November, 2010.
- “Oligonucleotide Microarray analysis of genomic imbalances to detect gene fusions in cancer”. https://agilenteseminar.webex.com/agilenteseminar/lsr.php?AT=pb&SP=EC&rID=4014382&rKey=5386aff4f4b57c73. July, 2011.
- Elucidating tumor heterogeneity in prostate cancer by combined IHC & novel RNA ISHhttps://www.youtube.com/watch?v=PvWoyBcz7aA
- Elucidating tumor heterogeneity in prostate cancer by combined IHC and novel RNA ISHhttp://www.acdbio.com/science/scientific-resources/upcoming-webinars/